GlassScriptPhysician profile
Monica L Meyer
NPI 1285638825
$1,759.08
in general payments reported to CMS, 2019-2025
24 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $217 · 2021: $371 · 2022: $212 · 2023: $242 · 2024: $226 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $480 · Education: $94.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.04 |
| Education | $94.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $248.00 | 2022-2025 | Veozah |
| Pfizer INC. | $180.30 | 2019-2023 | |
| Amgen INC. | $177.47 | 2019-2025 | Evenity, Prolia |
| Exeltis, USA INC. | $131.22 | 2019-2025 | Slynd, Nuvessa |
| Therapeuticsmd, INC. | $121.18 | 2019-2021 | |
| Avion Pharmaceuticals | $109.82 | 2019-2023 | Balcoltra |
| Millicent US INC | $98.95 | 2019-2024 | Intrarosa, Femring |
| Abbvie INC. | $97.83 | 2019-2023 | |
| Medtronic, INC. | $95.14 | 2022 | |
| Evofem Biosciences, INC. | $84.72 | 2021-2022 | |
| Novo Nordisk INC | $44.85 | 2022-2025 | Wegovy |
| Organon LLC | $44.43 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $44.03 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $43.04 | 2021-2023 | |
| Allergan, INC. | $42.63 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $41.54 | 2019 | |
| Virtus Pharmaceuticals LLC | $39.66 | 2021 | |
| Lupin INC. | $28.06 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $15.00 | 2019 | |
| Bausch Health US, LLC | $15.00 | 2019 | |
| Sumitomo Pharma America, INC. | $14.81 | 2023 | Myfembree |
| Duchesnay USA Incorporated | $14.81 | 2019 | |
| Ascend Therapeutics US, LLC | $13.80 | 2021 | |
| Agile Therapeutics, INC. | $12.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.